A5100314153- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- CNS Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Private Equity and Venture Capital
Sun Yat-sen University
2025
Sun Yat-sen University Cancer Center
2025
Nanjing University of Chinese Medicine
2024
Jiangsu Province Hospital
2024
Genetic alterations of chronic active B-cell receptor signaling often occur in primary central nervous system lymphoma (PCNSL). We conducted a phase-II trial high-dose methotrexate plus ibrutinib and temozolomide (MIT) the treatment newly diagnosed PCNSL. A total 35 patients were enrolled, with 33 included analysis. The best overall response rate was 93.9% complete 72.7% for induction therapy. 2-year progression-free survival (PFS) 57.6% (95%CI: 49.0-66.2) 84.8% 78.6-91.0). incidence grade ≧...
The aim of this study was to investigate the prognostic value baseline PET/CT parameters alone and combined with clinical features in Extranodal Natural killer/T-cell lymphoma (ENKTL) patients treated P-GEMOX regimen (pegaspargase, gemcitabine oxaliplatin). A total 97 were retrospectively evaluated. relationships between PETCT metabolic survival tested using Cox regression analysis receiver operating characteristic(ROC) curve employed evaluate optimal cut-off these parameters. Kaplan–Meier...